Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,657,340 papers from all fields of science
Search
Sign In
Create Free Account
IGHV3-21 gene
Known as:
IGHV3-21
, Immunoglobulin Heavy Variable 3-21 Gene
, immunoglobulin heavy variable 3-21
This gene is involved in immunoglobulin heavy chain structure.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
Humoral Immunity
Immune System Processes
Protein IGHV3-21, Human
Broader (1)
IGHV@ gene cluster
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
The anti-nonGal xenoantibody response to α1,3-galactosyltransferase gene knockout pig xenografts
I. Harnden
,
Kathleen L. Kiernan
,
M. Kearns-Jonker
Current Opinion in Organ Transplantation
2010
Corpus ID: 29348440
Purpose of reviewAnti-nonGal xenoantibodies are a major barrier to the survival of genetically modified porcine xenografts. This…
Expand
2008
2008
The Anti‐Non‐Gal Xenoantibody Response to Xenoantigens on Gal Knockout Pig Cells Is Encoded by a Restricted Number of Germline Progenitors
Kathleen L. Kiernan
,
I. Harnden
,
Mirja Gunthart
,
C. Gregory
,
Jessica A Meisner
,
M. Kearns-Jonker
American Journal of Transplantation
2008
Corpus ID: 21076614
Antibodies directed at non‐gal xenoantigens are responsible for acute humoral xenograft rejection when gal knockout (GalTKO) pig…
Expand
2007
2007
KDE Analysis in Chronic Lymphocytic Leukemia Patients with B Cells Expressing IGHV3-21 and Discordant Mutational Status between Heavy and Light Chain.
Emanuela M. Ghia
,
L. Rassenti
,
G. Widhopf
,
G. Silverman
,
Andrew W. Greaves
,
T. Kipps
2007
Corpus ID: 90953373
Patients with chronic lymphocytic leukemia (CLL) cells that use IGHV3-21 typically have aggressive disease similar to that of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE